Found: 6
Select item for more details and to access through your institution.
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2--Technical).
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 2, p. 239, doi. 10.2967/jnumed.122.264124
- By:
- Publication type:
- Article
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1--Clinical).
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 1, p. 102, doi. 10.2967/jnumed.122.264106
- By:
- Publication type:
- Article
APPLICATION OF THE LUGANO CLASSIFICATION FOR INITIAL EVALUATION, STAGING, AND RESPONSE ASSESSMENT OF HODGKIN AND NON-HODGKIN LYMPHOMA: THE PROLOG CONSENSUS INITIATIVE (PART 1- CLINICAL).
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.122.264106
- By:
- Publication type:
- Article
APPLICATION OF THE LUGANO CLASSIFICATION FOR INITIAL EVALUATION, STAGING, AND RESPONSE ASSESSMENT OF HODGKIN AND NON-HODGKIN LYMPHOMA: THE PROLOG CONSENSUS INITIATIVE (PART 2- TECHNICAL).
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.122.264124
- By:
- Publication type:
- Article
APPLICATION OF THE LUGANO CLASSIFICATION FOR INITIAL EVALUATION, STAGING, AND RESPONSE ASSESSMENT OF HODGKIN AND NON-HODGKIN LYMPHOMA: THE PROLOG CONSENSUS INITIATIVE (PART 1- CLINICAL).
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.122.264106
- By:
- Publication type:
- Article
Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09).
- Published in:
- Therapeutic Advances in Medical Oncology, 2018, v. 10, n. 1, p. 1, doi. 10.1177/1758835918807339
- By:
- Publication type:
- Article